Skip to main content
OKYO Pharma Ltd logo

OKYO Pharma Ltd — Investor Relations & Filings

Ticker · OKYO ISIN · US6793451088 US Manufacturing
Open in API
Filings indexed 274 across all filing types
Latest filing 2018-03-09 Declaration of Voting R…
Country US United States of America
Listing US OKYO

About OKYO Pharma Ltd

https://okyopharma.com/

OKYO Pharma Ltd. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for inflammatory eye diseases and chronic pain. The company's primary focus is on addressing significant unmet medical needs in neuropathic corneal pain (NCP) and dry eye disease (DED). Its lead product candidate, Urcosimod (OK-101), is a novel G protein-coupled receptor (GPCR) agonist that targets the chemerin receptor to produce anti-inflammatory and pain-reducing effects. OKYO is the first company to receive Investigational New Drug (IND) clearance from the FDA to clinically evaluate a drug specifically for NCP, a condition with no approved treatments. Urcosimod has also been granted Fast Track Designation by the FDA for the treatment of NCP.

Recent filings

Filing Released Lang Actions
Result of General Meeting and Corporate Update
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official announcement from OKYO Pharma Corporation regarding the results of a General Meeting held on March 9, 2018. It explicitly states that the resolution put to shareholders was passed, covering items such as a name change, migration to Guernsey, and the cancellation of admission to AIM. Because the document reports the official outcome of a shareholder vote at a general meeting, it falls under the category of Declaration of Voting Results.
2018-03-09 English
Change of Broker
Regulatory Filings Classification · 98% confidence The document is a short announcement (under 5,000 characters) issued via the Regulatory News Service (RNS) regarding a change in the company's broker due to the insolvency of their previous broker. It does not contain financial statements, board appointments, or other specific report types, but rather serves as a general regulatory update regarding company operations and compliance. Therefore, it falls under the RNS category.
2018-03-02 English
Proposed cancellation, suspension, notice of GM
Delisting Announcement Classification · 95% confidence The document is an official announcement from OKYO Pharma Corporation regarding a 'Proposed Cancellation' of its shares from the AIM market and a 'Notice of General Meeting' to seek shareholder approval for this action. It includes a 'Letter from the Chairman' and details the rationale for the cancellation, the impact on shareholders, and the procedural steps for the upcoming meeting. While it contains a notice of a meeting, it is primarily a regulatory announcement regarding a fundamental corporate change (delisting/cancellation of trading), which fits the 'Delisting Announcement' category.
2018-02-21 English
Suspension - Okyo Pharma Corporation
Regulatory Filings Classification · 98% confidence The document is a short notice from the London Stock Exchange's RNS (Regulatory News Service) announcing a temporary suspension of trading for OKYO PHARMA CORPORATION. Since it is a regulatory announcement regarding trading status rather than a financial report, M&A activity, or share issuance, it falls under the general regulatory filing category.
2018-02-21 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.